Rheumatology · Phase 2-3 · pulled 2026-11-06

Rheumatoid arthritis: trial sites and investigators

25 sites and 10 investigators from 213 completed and terminated Phase 2-3 trials of rheumatoid arthritis (last 12 years), plus 80 trials recruiting now.

A cited data summary, not a recommendation to select or exclude any site. Every line links to the registry record behind it.

Sites

Sites are listed in the registry's own order: comparable trials listed (most first), ties by latest completion, then name. The Sitecite score is a second column. “Competing now” counts recruiting, active and not-yet-recruiting trials in the same indication at that site.

Rheumatoid arthritis: sites in the registry's trial-count order, with the Sitecite score as a second column
#	Site	Comparable trials listed	Trials (ClinicalTrials.gov)	Latest completion	Competing now	Score (0-100)
1	Altoona Center for Clinical Research Duncansville, United States · 8 spellings merged	27 22 completed, 5 terminated	NCT06859294 NCT06073093 NCT03025308 6 trials with titles NCT06859294 A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis terminated 2026-06-05 Stop reason on the record: “The interim analysis data failed to demonstrate the intended treatment effect.” NCT06073093 A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis completed 2025-07-02 NCT03025308 Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis completed 2025-05-16 NCT05516758 A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis terminated 2025-01-17 Stop reason on the record: “Study terminated due to an unfavourable benefit-risk profile observed in interim data analysis.” NCT05363891 Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis completed 2024-10-31 NCT06028438 A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis completed 2024-10-29	2026-06-05	5 NCT07137598 NCT07704580 NCT07176390 NCT04692493	89
2	MEDICAL PLUS s.r.o. Uherské Hradiště, Czechia · 7 spellings merged	20 20 completed, 0 terminated	NCT05848258 NCT03025308 NCT05198310 6 trials with titles NCT05848258 An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis completed 2026-04-22 NCT03025308 Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis completed 2025-05-16 NCT05198310 Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor completed 2024-05-06 NCT05460832 Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA completed 2024-01-03 NCT03926195 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis completed 2023-05-10 NCT04634253 A Study of LY3462817 in Participants With Rheumatoid Arthritis completed 2022-06-29	2026-04-22	0	91
3	Accurate Clinical Research Houston, United States · 6 spellings merged	15 12 completed, 3 terminated	NCT06859294 NCT05848258 NCT05516758 6 trials with titles NCT06859294 A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis terminated 2026-06-05 Stop reason on the record: “The interim analysis data failed to demonstrate the intended treatment effect.” NCT05848258 An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis completed 2026-04-22 NCT05516758 A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis terminated 2025-01-17 Stop reason on the record: “Study terminated due to an unfavourable benefit-risk profile observed in interim data analysis.” NCT05363891 Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis completed 2024-10-31 NCT04991753 A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis completed 2022-08-10 NCT04268771 A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products completed 2022-04-20	2026-06-05	0	89
4	Institute of Rheumatology Belgrade, Serbia · 7 spellings merged	15 15 completed, 0 terminated	NCT03025308 NCT05460832 NCT04512001 6 trials with titles NCT03025308 Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis completed 2025-05-16 NCT05460832 Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA completed 2024-01-03 NCT04512001 MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis completed 2022-06-06 NCT04230213 A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis completed 2021-06-22 NCT03233230 Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis completed 2019-09-23 NCT02983227 A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350 completed 2019-07-17	2025-05-16	1 NCT07409103	94
5	Vital Medical Center Veszprém, Hungary · 6 spellings merged	14 13 completed, 1 terminated	NCT05848258 NCT05516758 NCT06028438 6 trials with titles NCT05848258 An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis completed 2026-04-22 NCT05516758 A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis terminated 2025-01-17 Stop reason on the record: “Study terminated due to an unfavourable benefit-risk profile observed in interim data analysis.” NCT06028438 A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis completed 2024-10-29 NCT04634253 A Study of LY3462817 in Participants With Rheumatoid Arthritis completed 2022-06-29 NCT04512001 MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis completed 2022-06-06 NCT04413617 TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE completed 2022-02-07	2026-04-22	0	88
6	Inland Rheumatology Clinical Trials, Inc. Upland, United States · 4 spellings merged	14 14 completed, 0 terminated	NCT03025308 NCT05363891 NCT06028438 6 trials with titles NCT03025308 Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis completed 2025-05-16 NCT05363891 Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis completed 2024-10-31 NCT06028438 A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis completed 2024-10-29 NCT05198310 Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor completed 2024-05-06 NCT04991753 A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis completed 2022-08-10 NCT04268771 A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products completed 2022-04-20	2025-05-16	2 NCT07137598 NCT04539964	94
7	Medvin Clinical Research Covina, United States · 3 spellings merged	12 9 completed, 3 terminated	NCT06859294 NCT03025308 NCT05516758 6 trials with titles NCT06859294 A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis terminated 2026-06-05 Stop reason on the record: “The interim analysis data failed to demonstrate the intended treatment effect.” NCT03025308 Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis completed 2025-05-16 NCT05516758 A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis terminated 2025-01-17 Stop reason on the record: “Study terminated due to an unfavourable benefit-risk profile observed in interim data analysis.” NCT05363891 Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis completed 2024-10-31 NCT05198310 Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor completed 2024-05-06 NCT03120949 Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis completed 2021-09-01	2026-06-05	1 NCT04539964	85
8	Revmatologicky ustav Prague, Czechia · 2 spellings merged	12 12 completed, 0 terminated	NCT03025308 NCT03926195 NCT04512001 6 trials with titles NCT03025308 Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis completed 2025-05-16 NCT03926195 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis completed 2023-05-10 NCT04512001 MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis completed 2022-06-06 NCT04413617 TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE completed 2022-02-07 NCT03120949 Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis completed 2021-09-01 NCT04230213 A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis completed 2021-06-22	2025-05-16	0	100
9	Centrum Medyczne AMED Warsaw, Poland · 6 spellings merged	11 11 completed, 0 terminated	NCT03025308 NCT05460832 NCT03926195 6 trials with titles NCT03025308 Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis completed 2025-05-16 NCT05460832 Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA completed 2024-01-03 NCT03926195 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis completed 2023-05-10 NCT04991753 A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis completed 2022-08-10 NCT04512001 MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis completed 2022-06-06 NCT02504268 Effects of Abatacept in Patients With Early Rheumatoid Arthritis completed 2020-03-19	2025-05-16	0	91
10	Institute of Treatment and Rehabilitation "Niska Banja" Niška Banja, Serbia · 6 spellings merged	11 11 completed, 0 terminated	NCT03025308 NCT05460832 NCT04230213 6 trials with titles NCT03025308 Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis completed 2025-05-16 NCT05460832 Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA completed 2024-01-03 NCT04230213 A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis completed 2021-06-22 NCT03233230 Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis completed 2019-09-23 NCT02983227 A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350 completed 2019-07-17 NCT02996500 Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate completed 2018-08-15	2025-05-16	0	94
11	UMHAT "Kaspela", EOOD Plovdiv, Bulgaria · 8 spellings merged	11 11 completed, 0 terminated	NCT03025308 NCT05842213 NCT03120949 6 trials with titles NCT03025308 Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis completed 2025-05-16 NCT05842213 Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX completed 2024-09-24 NCT03120949 Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis completed 2021-09-01 NCT02983227 A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350 completed 2019-07-17 NCT02760368 Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease completed 2018-10-01 NCT03052322 MSB11022 in Moderate to Severe Rheumatoid Arthritis completed 2018-08-27	2025-05-16	0	94
12	Szpital Uniwersytecki nr 2 im.dr J. Biziela Bydgoszcz, Poland · 4 spellings merged	11 11 completed, 0 terminated	NCT03926195 NCT03120949 NCT02760407 6 trials with titles NCT03926195 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis completed 2023-05-10 NCT03120949 Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis completed 2021-09-01 NCT02760407 Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease completed 2019-11-05 NCT02760433 Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease completed 2019-10-01 NCT02983227 A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350 completed 2019-07-17 NCT03052322 MSB11022 in Moderate to Severe Rheumatoid Arthritis completed 2018-08-27	2023-05-10	0	93
13	Arizona Arthritis and Rheumatology Research, PLLC Mesa, United States · 9 spellings merged	10 8 completed, 2 terminated	NCT06859294 NCT05516758 NCT04991753 6 trials with titles NCT06859294 A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis terminated 2026-06-05 Stop reason on the record: “The interim analysis data failed to demonstrate the intended treatment effect.” NCT05516758 A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis terminated 2025-01-17 Stop reason on the record: “Study terminated due to an unfavourable benefit-risk profile observed in interim data analysis.” NCT04991753 A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis completed 2022-08-10 NCT04634253 A Study of LY3462817 in Participants With Rheumatoid Arthritis completed 2022-06-29 NCT02504268 Effects of Abatacept in Patients With Early Rheumatoid Arthritis completed 2020-03-19 NCT02760407 Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease completed 2019-11-05	2026-06-05	2 NCT07176390 NCT04539964	86
14	Seoul National University Hospital Seoul, South Korea · 2 spellings merged	10 10 completed, 0 terminated	NCT03025308 NCT05069714 NCT03618784 6 trials with titles NCT03025308 Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis completed 2025-05-16 NCT05069714 One or Two Week Methotrexate Discontinuation on Efficacy of Influenza Vaccination in Rheumatoid Arthritis. completed 2022-09-30 NCT03618784 Safety and Efficacy of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis completed 2022-05-13 NCT03275025 A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis completed 2019-11-19 NCT02996500 Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate completed 2018-08-15 NCT02833350 Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) completed 2018-07-02	2025-05-16	0	94
15	Southwest Rheumatology Research LLC Mesquite, United States · 4 spellings merged	10 9 completed, 1 terminated	NCT03025308 NCT05363891 NCT06028438 6 trials with titles NCT03025308 Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis completed 2025-05-16 NCT05363891 Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis completed 2024-10-31 NCT06028438 A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis completed 2024-10-29 NCT05198310 Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor completed 2024-05-06 NCT04991753 A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis completed 2022-08-10 NCT02538341 Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial) completed 2020-12-01	2025-05-16	2 NCT07704580 NCT04539964	86
16	Medycyna Kliniczna Warsaw, Poland · 2 spellings merged	10 10 completed, 0 terminated	NCT03926195 NCT04512001 NCT04413617 6 trials with titles NCT03926195 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis completed 2023-05-10 NCT04512001 MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis completed 2022-06-06 NCT04413617 TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE completed 2022-02-07 NCT03120949 Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis completed 2021-09-01 NCT02760407 Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease completed 2019-11-05 NCT03233230 Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis completed 2019-09-23	2023-05-10	0	92
17	UMHAT Sv. Ivan Rilski EAD Sofia, Bulgaria · 5 spellings merged	10 10 completed, 0 terminated	NCT03926195 NCT03120949 NCT04577781 6 trials with titles NCT03926195 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis completed 2023-05-10 NCT03120949 Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis completed 2021-09-01 NCT04577781 A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate completed 2021-04-07 NCT02760407 Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease completed 2019-11-05 NCT02760368 Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease completed 2018-10-01 NCT03052322 MSB11022 in Moderate to Severe Rheumatoid Arthritis completed 2018-08-27	2023-05-10	0	96
18	Peking Union Medical College Hospital Beijing, China · 4 spellings merged	9 9 completed, 0 terminated	NCT06020144 NCT06800157 NCT05133297 6 trials with titles NCT06020144 A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs completed 2026-08-20 NCT06800157 Study of LW402 Tablets in Moderate to Severe Rheumatoid Arthritis completed 2024-08-30 NCT05133297 The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis completed 2023-05-30 NCT06099535 A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis completed 2023-04-11 NCT03016013 A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis. completed 2022-12-29 NCT06048224 Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis completed 2022-01-31	2026-08-20	5 NCT07408024 NCT06887127 NCT07639177 NCT06276998	100
19	Arizona Arthritis & Rheumatology Associates, P.C. Phoenix, United States · 6 spellings merged	9 7 completed, 2 terminated	NCT06859294 NCT03025308 NCT05516758 6 trials with titles NCT06859294 A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis terminated 2026-06-05 Stop reason on the record: “The interim analysis data failed to demonstrate the intended treatment effect.” NCT03025308 Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis completed 2025-05-16 NCT05516758 A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis terminated 2025-01-17 Stop reason on the record: “Study terminated due to an unfavourable benefit-risk profile observed in interim data analysis.” NCT04634253 A Study of LY3462817 in Participants With Rheumatoid Arthritis completed 2022-06-29 NCT03120949 Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis completed 2021-09-01 NCT02760407 Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease completed 2019-11-05	2026-06-05	1 NCT07779616	84
20	Investigacion y Biomedicina de Chihuahua, S.C. Chihuahua City, Mexico · 3 spellings merged	9 8 completed, 1 terminated	NCT05848258 NCT03025308 NCT05516758 6 trials with titles NCT05848258 An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis completed 2026-04-22 NCT03025308 Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis completed 2025-05-16 NCT05516758 A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis terminated 2025-01-17 Stop reason on the record: “Study terminated due to an unfavourable benefit-risk profile observed in interim data analysis.” NCT04634253 A Study of LY3462817 in Participants With Rheumatoid Arthritis completed 2022-06-29 NCT03120949 Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis completed 2021-09-01 NCT02760407 Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease completed 2019-11-05	2026-04-22	1 NCT07137598	88
21	Ai Centrum Medyczne Poznan, Poland · 4 spellings merged	9 8 completed, 1 terminated	NCT03025308 NCT05516758 NCT03926195 6 trials with titles NCT03025308 Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis completed 2025-05-16 NCT05516758 A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis terminated 2025-01-17 Stop reason on the record: “Study terminated due to an unfavourable benefit-risk profile observed in interim data analysis.” NCT03926195 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis completed 2023-05-10 NCT04512001 MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis completed 2022-06-06 NCT04413617 TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE completed 2022-02-07 NCT02983227 A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350 completed 2019-07-17	2025-05-16	0	89
22	CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica San Juan, Argentina · 6 spellings merged	9 7 completed, 2 terminated	NCT03025308 NCT05516758 NCT03120949 6 trials with titles NCT03025308 Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis completed 2025-05-16 NCT05516758 A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis terminated 2025-01-17 Stop reason on the record: “Study terminated due to an unfavourable benefit-risk profile observed in interim data analysis.” NCT03120949 Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis completed 2021-09-01 NCT02760407 Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease completed 2019-11-05 NCT02760433 Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease completed 2019-10-01 NCT03233230 Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis completed 2019-09-23	2025-05-16	1 NCT07137598	85
23	ClinicMed Daniluk, Nowak Sp. J. Bialystok, Poland · 6 spellings merged	9 9 completed, 0 terminated	NCT03025308 NCT05460832 NCT04049448 6 trials with titles NCT03025308 Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis completed 2025-05-16 NCT05460832 Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA completed 2024-01-03 NCT04049448 Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis completed 2023-01-23 NCT04512001 MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis completed 2022-06-06 NCT04413617 TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE completed 2022-02-07 NCT03813199 Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis completed 2021-04-27	2025-05-16	0	92
24	Physician Research Collaboration, LLC Lincoln, United States · 4 spellings merged	9 8 completed, 1 terminated	NCT03025308 NCT05246280 NCT04634253 6 trials with titles NCT03025308 Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis completed 2025-05-16 NCT05246280 Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA terminated 2024-07-09 Stop reason on the record: “Sponsor Decision” NCT04634253 A Study of LY3462817 in Participants With Rheumatoid Arthritis completed 2022-06-29 NCT03120949 Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis completed 2021-09-01 NCT03938636 Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging completed 2021-06-30 NCT02504268 Effects of Abatacept in Patients With Early Rheumatoid Arthritis completed 2020-03-19	2025-05-16	2 NCT07176390 NCT04539964	97
25	Accurate Clinical Management LLC Houston, United States · 6 spellings merged	9 8 completed, 1 terminated	NCT05516758 NCT05363891 NCT04268771 6 trials with titles NCT05516758 A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis terminated 2025-01-17 Stop reason on the record: “Study terminated due to an unfavourable benefit-risk profile observed in interim data analysis.” NCT05363891 Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis completed 2024-10-31 NCT04268771 A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products completed 2022-04-20 NCT02996500 Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate completed 2018-08-15 NCT02833350 Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) completed 2018-07-02 NCT02640612 Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis completed 2017-11-01	2025-01-17	2 NCT07620392 NCT07137598	91

Investigators

Principal investigators and study chairs of the comparable trials, most trials first. Papers are matched on name, affiliation and condition; the match confidence is shown on each.

Rheumatoid arthritis: principal investigators and study chairs of the comparable trials, with matched papers
#	Investigator	Comparable trials	Trials (ClinicalTrials.gov)	Papers (PubMed)
1	Zhanguo Li Peking University People's Hospital	4	NCT07335952 NCT05576597 NCT05957107 NCT02467504	PMID 42966456 International journal of pharmaceutics, 2026 · Medium match PMID 42937806 Medicine, 2026 · High match PMID 42904266 Regenerative biomaterials, 2026 · Medium match
2	Xiaofeng Zeng Peking Union Medical College Hospital	4	NCT06099535 NCT03830203 NCT03522415 NCT03254966	PMID 42923801 Rheumatology and immunology research, 2026 · High match PMID 42907852 Journal of nanobiotechnology, 2026 · High match PMID 42312387 Arthritis & rheumatology (Hoboken, N.J.), 2026 · High match
3	Roman Ivanov Biocad	3	NCT03455842 NCT02762838 NCT02744196	No paper matched at High or Medium confidence
4	Ellen-Margrethe Hauge Aarhus University Hospital	2	NCT04004429 NCT02944799	PMID 42939661 Biomolecules, 2026 · High match PMID 42730963 Clinical rheumatology, 2026 · High match PMID 42368606 EULAR rheumatology open, 2026 · High match
5	Yin Su Peking University People's Hospital	2	NCT03478111 NCT03275025	PMID 42871040 Frontiers in surgery, 2026 · High match PMID 42804139 Irish journal of medical science, 2026 · High match PMID 42711633 Clinical rheumatology, 2026 · Medium match
6	José Costa Unidade Local de Saúde do Alto Minho, EPE	1	NCT06565273	PMID 31249276 Acta reumatologica portuguesa, 2020 · High match
7	Antoine BENARD University Hospital, Bordeaux	1	NCT04196868	No paper matched at High or Medium confidence
8	Christophe RICHEZ University Hospital, Bordeaux	1	NCT04196868	PMID 42896926 The Lancet. Rheumatology, 2026 · Medium match PMID 42419787 RMD open, 2026 · High match PMID 42049394 RMD open, 2026 · High match
9	Radiyati Umi Partan Universitas Sriwijaya	1	NCT07715045	PMID 42292144 Therapeutic advances in musculoskeletal disease, 2026 · High match
10	Stephen Hall Emeritus Research	1	NCT05942911	PMID 40461266 RMD open, 2025 · High match PMID 39059811 RMD open, 2024 · High match PMID 39053948 RMD open, 2024 · High match

How to read this

Sites are counted from the facility lists on the registry record, with spelling variants merged. “Listed on the trial” means the registry shows the site as a location; it is not a count of patients enrolled. The method, the formula and the published tests.

Want this for your own protocol or your CRO's list?

Leave your indication and the CRO's names. We reply by email with each one checked against these records.